Oral bioavailability of cantharidin-loaded solid lipid nanoparticles

Chinese Medicine (United Kingdom)

Volumn 8, Issue 1, 2013, Pages

  Dang, Yun Jie ^a   Zhu, Chun Yan ^a  

^a INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANTHARIDIN; SOLID LIPID NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; GAS CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MASS FRAGMENTOGRAPHY; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY;

EID: 84871950662     PISSN: None     EISSN: 17498546     Source Type: Journal    
DOI: 10.1186/1749-8546-8-1     Document Type: Article

References (23)

1. Wang GS. Medical uses of mylabris in ancient china and recent studies. J. Ethno pharmacol 1989, 26:147-162.
2. Walter WG, Cole F. Isolation of cantharidin from epicauta pestifera. J Pharm Sci 1967, 56:174-176. 10.1002/jps.2600560204, 6025768.
3. Einbinder JM, Parshley MS, Walzer RA, Sanders SL. The effect of cantharidin on epithelial cells in tissue culture. J Invest Dermatol 1969, 52:291-303.
4. Zhang JP, Ying K, Xiao ZY. Analysis of gene expression profiles in human HL-60 cell exposed to cantharidin using cDNA microarray. Int J Cancer 2004, 108:212-218. 10.1002/ijc.11405, 14639605.
5. Efferth T, Rauh R. Molecular modes of action of cantharidin in tumor cells biochem. Pharmacol 2005, 69:811-818.
6. Xu B. Pharmacology of some natural products of china. Trends Pharmacol Sci 1981, 2:271-272.
7. Wang CC, Wu CH, Hsieh KJ, Yen KY, Yang LL. Cytotoxic effects of cantharidin on the growth of normal and carcinoma cells. Toxicology 2000, 2:77-87.
8. Oaks WW, Ditunno JF, Magnani T, Levy HA, Mills LC. Cantharidin poisoning. Arch Intern Med 1960, 105:106-114.
9. Craven JD, Polak A. Cantharidin poisoning. Br Med J 1954, 2:1386-1388. 10.1136/bmj.2.4901.1386, 2080313, 20788368.
10. Dang Y-J, Zhu C-Y. Determination of trace cantharidin in plasma and pharmacokinetic study in beagle dogs using Gas chromatography-mass spectrometry. J Anal Toxicol 2009, 7:383-388.
11. Zhang JP, Ying K. Analysis of gene expression profiles in human HL-60 cell exposed to cantharidin using DNA microarray. J Cancer 2004, 108:211-218.
12. Moed L, Shwayder TA, Chang MW. Cantharidin revisited: a blistering defense of an ancient medicine. Arch Dermatol 2001, 137:1357-1360.
13. Dang Y-J, Hu C-H, An L-N, Zhu C-Y. Study of the physicochemical properties and oral bioavailability of the solid dispersion of cantharidin with polyethylene glycol 4000. Methods Find Exp Clin Pharmacol 2010, 32:157-162. 10.1358/mf.2010.32.3.1423886, 20448857.
14. Yunjie D, Hu AL, Chunhui ZC. Inclusion complex of cantharidin with β-cyclodextrin: preparation, characterization, in vitro and in vivo evaluation. J Appl Polym Sci 2012, 123:1557-1562.
15. Matsuzawa M, Graziano M, Casida J. Endothal and cantharidin analogues: relation of structure to herbicidal activity and mammalian toxicity. J Agric Food Chem 1987, 35:823-829.
16. Peter K, Muller RH. European Symposium on formulation of Poorly-available Drug for Oral Administration 1996, 330-333. Paris: APGI.
17. Muller RH, Mehnert K. Solid lipid nanoparticles (SLN)-an alternative colloidal carrier system for controlled drug delivery. Eur. J. Phar. Biopham 1995, 41:62-69.
18. Müller RH, Runge SA. Submicron emulsions in drug targeting and delivery. CRC Press 1998, 9:219-234.
19. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001, 47:3-19. 10.1016/S0169-409X(00)00118-6, 11251242.
20. Cavalli R, Marengo E, Rodriguez L, Gasco MR. Effects of some experimental factors on the production process of solid lipid nanoparticles. Eur J Pharm Biopharm 1996, 43:110-115.
21. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles(SLN) for controlled drug delivery-a review of the state of art. Eur J Pharm Biopharm 2000, 50:161-177. 10.1016/S0939-6411(00)00087-4, 10840199.
22. Kesisoglou F, Panmai S, Wu YH. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007, 59:631-644. 10.1016/j.addr.2007.05.003, 17601629.
23. Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 1999, 16:751-757. 10.1023/A:1018888927852, 10350020.